Emcure Pharma stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5 as the company announced a distribution and promotion partnership with Sanofi India
Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes
Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE
Emcure Pharma hit 10 per cent upper circuit after the pharma company's Q4 net profit stood at ₹197.2 crore as against ₹121 crore, up 62 per cent
Emcure Pharma posted strong March quarter results with 63% rise in net profit and 19.5% growth in revenue, driven by robust domestic demand and global segment performance
The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range
The stock was listed on July 10, 2024, and made a stellar debut on Indian bourses with the shares getting listed at Rs 1,325.05 on the BSE, a 31.45 per cent premium over its issue price
Shares of Emcure Pharma jumped 6 per cent at Rs 1523.80 a piece on the BSE after the company reported a strong second quarter earnings for the financial year 2024-25 (Q2FY25)
The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure
Emcure Pharmaceuticals listing today: According to analysts, Emcure Pharma is quoting at a reasonable valuation with a niche opportunity to invest in the gynaecology & HIV antivirals therapeutic areas
Emcure Pharmaceuticals listing: Stock made a strong market debut as they got listed at Rs 1,325, a 31 per cent premium over the issue price of Rs 1,008 on the NSE and BSE today
Stocks to watch on July 10: Emcure Pharmaceuticals' shares are scheduled to make their debut on the stock exchanges on Wednesday
The demand for both issuances reflects the positive sentiment among investors and could be a harbinger for more initial public offerings (IPOs) in the coming weeks, said industry players
The issue, with a price band of Rs 960 to Rs 1,008 per share, will be open for public subscription till July 5. The IPO comprises fresh issuance of equity shares worth Rs 800 crore
Emcure Pharmaceuticals initial public offering is set to open for subscription on Wednesday, July, 3, 2024
Emcure Pharmaceuticals' shares are commanding a premium of over 25 per cent above their price band
Fourth largest IPO of 2024; company will use the proceeds to repay debt and for general corporate purposes
IPO comprises fresh issue of equity shares worth Rs 800 crore and OFS of 13.6 million equity shares by promoters
Litigation before courts in the US and arbitral tribunal in London settled, two sides say
MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas